Chagas disease: Present status of pathogenic mechanisms and chemotherapy

Biological Research

Volumn 43, Issue 3, 2010, Pages 323-331

  Maya, Juan Diego ^a   Orellana, Myriam ^a   Ferreira, Jorge ^a   Kemmerling, Ulrike ^a   López Muñoz, Rodrigo ^a   Morello, Antonio ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Chagas disease; Chemotherapy; Nifurtimox; Prostaglandins; Trypanosoma cruzi

Indexed keywords

MASTIGOPHORA (FLAGELLATES); MUS; PROTOZOA; TRYPANOSOMA CRUZI;

EID: 78650059497     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.4067/S0716-97602010000300009     Document Type: Article

References (111)

1. ABDALLA, G. K., FARIA, G. E., SILVA, K. T., CASTRO, E. C., REIS, M. A., and MICHELIN, M. A. (2008): Trypanosoma cruzi: the role of PGE2 in immune response during the acute phase of experimental infection. Exp Parasitol 118, 514-21.
2. APT, W., ARRIBADA, A., ZULANTAY, I., SOLARI, A., SANCHEZ, G., MUNDACA, K., CORONADO, X., RODRIGUEZ, J., GIL, L. C., and OSUNA, A. (2005): Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 99, 733-41.
3. ARAUJO-JORGE, T. C., WAGHABI, M. C., SOEIRO MDE, N., KERAMIDAS, M., BAILLY, S., and FEIGE, J. J. (2008): Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev 19, 405-13.
4. ASHTON, A. W., MUKHERJEE, S., NAGAJYOTHI, F. N., HUANG, H., BRAUNSTEIN, V. L., DESRUISSEAUX, M. S., FACTOR, S. M., LOPEZ, L., BERMAN, J. W., WITTNER, M., SCHERER, P. E., CAPRA, V., COFFMAN, T. M., SERHAN, C. N., GOTLINGER, K., WU, K. K., WEISS, L. M., and TANOWITZ, H. B. (2007): Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med 204, 929-40.
5. BELHASSEN, L., PELLE, G., DUBOISR-ANDE, J. L., and ADNOT, S. (2003): Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41, 1198-204.
6. BERN, C., MONTGOMERY, S. P., HERWALDT, B. L., RASSI, A., JR., MARIN-NETO, J. A., DANTAS, R. O., MAGUIRE, J. H., ACQUATELLA, H., MORILLO, C., KIRCHHOFF, L. V., GILMAN, R. H., REYES, P. A., SALVATELLA, R., and MOORE, A. C. (2007): Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298, 2171-81.
7. BESTETTI, R. B. and CARDINALLI-NETO, A. (2009): Prophylaxis of sudden cardiac death in chronic Chagas disease. Int J Cardiol 134, 428-9.
8. BRITTO, C. C. (2009): Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 104 Suppl 1, 122-35.
9. BUSTAMANTE, J. M., BIXBY, L. M., and TARLETON, R. L. (2008): Drug induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 14, 542-50.
10. CALDAS, I. S., TALVANI, A., CALDAS, S., CARNEIRO, C. M., DE LANA, M., DA MATTA GUEDES, P. M. and BAHIA, M. T. (2008): Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 103, 413-21.
11. CARDONI, R. L. and ANTÚNEZ, M. I. (2004): Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections. Mediators Inflamm 13, 235-40.
12. CASTRO, J. A., DE MECCA, M. M. and BARTEL, L. C. (2006): Toxic side effects of drugs used to treat Chagas disease (American trypanosomiasis). Hum Exp Toxicol 25, 471-9.
13. CAUGHEY, G. E., POULIOT, M., CLELAND, L. G. and JAMES, M. J. (1997): Regulation of tumor necrosis factor-alpha and IL-1 beta synthesis by thromboxane A2 in nonadherent human monocytes. J Immunol 158, 351-8.
14. CELENTANO, A. M., GORELIK, G., SOLANA, M. E., STERIN-BORDA, L., BORDA, E. and GONZALEZ CAPPA, S. M. (1995): PGE2 involvement in experimental infection with Trypanosoma cruzi subpopulations. Prostaglandins 49, 141-53.
15. CONSOLIM-COLOMBO, F. M., LOPES, H. F., ROSETTO, E. A., RUBIRA, M. C., BARRETO-FILHO, J. A., BARUZZI, A. C., ROCHA, N. N., MADY, C., IRIGOYEN, M. C. and KRIEGER, E. M. (2004): Endothelial function is preserved in Chagas heart disease patients without heart failure. Endothelium 11, 241-6.
16. COURA, J. R. (2009): Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104, 549-54.
17. COURA, J. R. and DIAS, J. C. (2009): Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 104 Suppl 1, 31-40.
18. CHESSLER, A. D., UNNIKRISHNAN, M., BEI, A. K., DAILY, J. P. and BURLEIGH, B. A. (2009): Trypanosoma cruzi triggers an early type I IFN response in vivo at the site of intradermal infection. J Immunol 182, 2288-96.
19. DANESE, S., DEJANA, E. and FIOCCHI, C. (2007): Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 178, 6017-22.
20. DAVILA, D. F., DONIS, J. H., TORRES, A., GOTTBERG, C. F., RAMONIPERAZZI, P. and ARATA DE BELLABARBA, G. (2008): Betaadrenergic blockers in chronic systolic heart failure secondary to Chagas disease. Int J Cardiol 128, 1-4.
21. DAVILA, D. F., ROSSELL, O. and DE BELLABARBA, G. A. (2002): Pathogenesis of chronic chagas heart disease: parasite persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation. Int J Parasitol 32, 107-9.
22. DE OLIVEIRA, F. A., TEIXEIRA VDE, P., LINO RDE, S., JR., VINAUD, M. C. and DOS REIS, M. A. (2007): Macroscopic aspects of chronic Chagas heart disease in aging. Arq Bras Cardiol 88, 486-90.
23. DE SOUZA, A. P., TANOWITZ, H. B., CHANDRA, M., SHTUTIN, V., WEISS, L. M., MORRIS, S. A., FACTOR, S. M., HUANG, H., WITTNER, M., SHIRANI, J. and JELICKS, L. A. (2004): Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection. Parasitol Res 92, 496-501.
24. DEBORGGRAEVE, S., CORONADO, X., SOLARI, A., ZULANTAY, I., APT, W., MERTENS, P., LAURENT, T., LECLIPTEUX, T., STESSENS, T., DUJARDIN, J. C., HERDEWIJN, P. and BUSCHER, P. (2009): T. cruzi OligoC-TesT: A Simplified and Standardized Polymerase Chain Reaction Format for Diagnosis of Chagas Disease. PLoS Negl Trop Dis 3, e450.
25. DIAS, W. B., FAJARDO, F. D., GRACASOUZA, A. V., FREIREDE-LIMA, L., VIEIRA, F., GIRARD, M. F., BOUTEILLE, B., PREVIATO, J. O., MENDONCA-PREVIATO, L. and TODESCHINI, A. R. (2008): Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi. Cell Microbiol 10, 88-99.
26. DOSREIS, G. A. and LOPES, M. F. (2009a): The importance of apoptosis for immune regulation in Chagas disease. Mem Inst Oswaldo Cruz 104, 259-62.
27. DOSREIS, G. A. and LOPES, M. F. (2009b): The importance of apoptosis for immune regulation in Chagas disease. Mem Inst Oswaldo Cruz 104 Suppl 1, 259-62.
28. DUBNER, S., SCHAPACHNIK, E., RIERA, A. R. and VALERO, E. (2008): Chagas disease: state-of-the-art of diagnosis and management. Cardiol J 15, 493-504.
29. DUFFY, T., BISIO, M., ALTCHEH, J., BURGOS, J. M., DIEZ, M., LEVIN, M. J., FAVALORO, R. R., FREILIJ, H. and SCHIJMAN, A. G. (2009): Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 3, e419.
30. DURAND, J. L., MUKHERJEE, S., COMMODARI, F., DE SOUZA, A. P., ZHAO, D., MACHADO, F. S., TANOWITZ, H. B. and JELICKS, L. A. (2009): Role of NO synthase in the development of Trypanosoma cruziinduced cardiomyopathy in mice. Am J Trop Med Hyg 80, 782-7.
31. EGAN, K. and FITZGERALD, G. A. (2006): Eicosanoids and the vascular endothelium. Handb Exp Pharmacol, 189-211.
32. FACTOR, S. M., CHO, S., WITTNER, M. and TANOWITZ, H. (1985): Abnormalities of the coronary microcirculation in acute murine Chagas disease. Am J Trop Med Hyg 34, 246-53.
33. FAÚNDEZ, M., LÓPEZ-MUNOZ, R., TORRES, G., MORELLO, A., FERREIRA, J., KEMMERLING, U., ORELLANA, M. and MAYA, J. D. (2008): Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas disease and enhances the efficacy of nifurtimox. Antimicrob Agents Chemother 52, 1837-9.
34. FAÚNDEZ, M., PINO, L., LETELIER, P., ORTIZ, C., LOPEZ, R., SEGUEL, C., FERREIRA, J., PAVANI, M., MORELLO, A. and MAYA, J. D. (2005): Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob Agents Chemother 49, 126-30.
35. FILARDI, L. S. and BRENER, Z. (1987): Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81, 755-9.
36. FIORELLI, A. I., STOLF, N. A., HONORATO, R., BOCCHI, E., BACAL, F., UIP, D., STRABELLI, T., ISSA, V., AMATO, V. A., FIORELLI, L. R. and OLIVEIRA, S. A. (2005): Later evolution after cardiac transplantation in Chagas disease. Transplant Proc 37, 2793-8.
37. FREIRE-DE-LIMA, C. G., NASCIMENTO, D. O., SOARES, M. B., BOZZA, P. T., CASTRO-FARIANETO, H. C., DE MELLO, F. G., DOSREIS, G. A. and LOPES, M. F. (2000): Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403, 199-203.
38. FREIRE-DE-LIMA, C. G., XIAO, Y. Q., GARDAI, S. J., BRATTON, D. L., SCHIEMANN, W. P. and HENSON, P. M. (2006): Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 281, 38376-84.
39. GANZINELLI, S., BORDA, E., JOENSEN, L. and STERIN-BORDA, L. (2009): Chagasic antibodies induce cardiac COX-2/iNOS mRNA expression with PGE2/NO production. Int J Cardiol 134, 212-23.
40. GARCÍA, S., RAMOS, C. O., SENRA, J. F., VILAS-BOAS, F., RODRIGUES, M. M., CAMPOS-DE-CARVALHO, A. C., RIBEIRO-DOS-SANTOS, R. and SOARES, M. B. (2005): Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob Agents Chemother 49, 1521-8.
41. GOIN, J. C., BORDA, E., LEIROS, C. P., STORINO, R. and STERINBORDA, L. (1994): Identification of antibodies with muscarinic cholinergic activity in human Chagas disease: pathological implications. J Auton Nerv Syst 47, 45-52.
42. GONZÁLEZ-GRANADO, L. I., ROJO-CONEJO, P., RUIZCON-TRERAS, J. and GONZÁLEZ-TOME, M. I. (2009): Chagas disease travels to Europe. Lancet 373, 2025.
43. GUTIÉRREZ, F. R., MINEO, T. W., PAVANELLI, W. R., GUEDES, P. M. and SILVA, J. S. (2009): The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 104, 236-45.
44. HARRIS, S. G., PADILLA, J., KOUMAS, L., RAY, D. and PHIPPS, R. P. (2002): Prostaglandins as modulators of immunity. Trends Immunol 23, 144-50.
45. HERNÁNDEZ, C. C., NASCIMENTO, J. H., CHAVES, E. A., COSTA, P. C., MASUDA, M. O., KURTENBACH, E., CAMPOS, D. E. C. A. C. and GIMENEZ, L. E. (2008): Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas disease. J Recept Signal Transduct Res 28, 375-401.
46. HERRERA, R. N., DÍAZ, E., PÉREZ AGUILAR, R., BIANCHI, J., BERMAN, S. and LUCIARDI, H. L. (2005): [Prothrombotic state in early stages of chronic Chagas disease. Its association with thrombotic risk factors]. Arch Cardiol Mex 75 Suppl 3, S3-38-48.
47. HERRERA, R. N., DÍAZ, E., PÉREZ, R., CHAIN, S., SANTY-ACUMO, R., RODRÍGUEZ, E., BIANCHI, J., COVIELLO, A., MIOTTI, J., FLORES, I., DE LA SERNA, F., MUNTANER, J., BERMAN, S. and LUCIARDI, H. (2003): [The prothrombotic state in early stages of chronic Chagas disease]. Rev Esp Cardiol 56, 377-82.
48. HIDEKO TATAKIHARA, V. L., CECCHINI, R., BORGES, C. L., MALVEZI, A. D., GRACA-DE SOUZA, V. K., YAMADAO-GATTA, S. F., RIZZO, L. V. and PINGE-FILHO, P. (2008): Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine Trypanosoma cruzi infection. FEMS Immunol Med Microbiol 52, 47-58.
49. HISS, F. C., LASCALA, T. F., MACIEL, B. C., MARÍN-NETO, J. A. and SIMOES, M. V. (2009): Changes in myocardial perfusion correlate with deterioration of left ventricular systolic function in chronic Chagas cardiomyopathy. JACC Cardiovasc Imaging 2, 164-72.
50. INAOKA, M., KIMISHIMA, M., TAKAHASHI, R. and SHIOHARA, T. (2006): Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells. Exp Dermatol 15, 981-90.
51. KUBATA, B. K., KABUTUTU, Z., NOZAKI, T., MUNDAY, C. J., FUKUZUMI, S., OHKUBO, K., LAZARUS, M., MARUYAMA, T., MARTIN, S. K., DUSZENKO, M. and URADE, Y. (2002): A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J Exp Med 196, 1241-51.
52. KURODA, E., NOGUCHI, J., DOI, T., UEMATSU, S., AKIRA, S. and YAMASHITA, U. (2007): IL-3 is an important differentiation factor for the development of prostaglandin E2-producing macrophages between C57BL/6 and BALB/c mice. Eur J Immunol 37, 2185-95.
53. KUSCHNIR, E., SGAMMINI, H., CASTRO, R., EVEQUOZ, C. and LEDESMA, R. (1983): [Chronic Chagas cardiomyopathy: effects of dipyradamole on ventricular dynamics]. Arq Bras Cardiol 41, 373-8.
54. LAUCELLA, S., DE TITTO, E. H., SEGURA, E. L., ORN, A. and ROTTENBERG, M. E. (1996): Soluble cell adhesion molecules in human Chagas disease: association with disease severity and stage of infection. Am J Trop Med Hyg 55, 629-34.
55. LOPES, M. F. and DOSREIS, G. A. (2000): Experimental Chagas disease: phagocytosis of apoptotic lymphocytes deactivates macrophages and fuels parasite growth. Apoptosis 5, 221-4.
56. MACHADO, C. R., CAMARGOS, E. R., GUERRA, L. B. and MOREIRA, M. C. (2000): Cardiac autonomic denervation in congestive heart failure: comparison of Chagas heart disease with other dilated cardiomyopathy. Hum Pathol 31, 3-10.
57. MARÍN-NETO, J. A., CUNHA-NETO, E., MACIEL, B. C. and SIMOES, M. V. (2007): Pathogenesis of chronic Chagas heart disease. Circulation 115, 1109-23.
58. MARÍN-NETO, J. A. and RASSI, A., JR. (2009): Update on Chagas heart disease on the first centenary of its discovery. Rev Esp Cardiol 62, 1211-6.
59. MARÍN-NETO, J. A., RASSI, A., JR., AVEZUM, A., JR., MATTOS, A. C. and RASSI, A. (2009): The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104, 319-24.
60. MARÍN-NETO, J. A., RASSI, A., JR., MORILLO, C. A., AVEZUM, A., CONNOLLY, S. J., SOSAESTANI, S., ROSAS, F. and YUSUF, S. (2008): Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156, 37-43.
61. MAYA, J. D., BOLLO, S., NÚNEZ-VERGARA, L. J., SQUELLA, J. A., REPETTO, Y., MORELLO, A., PERIE, J. and CHAUVIERE, G. (2003): Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol 65, 999-1006.
62. MAYA, J. D., CASSELS, B. K., ITURRIAGA-VÁSQUEZ, P., FERREIRA, J., FAUNDEZ, M., GALANTI, N., FERREIRA, A. and MORELLO, A. (2007): Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146, 601-20.
63. MAYA, J. D., REPETTO, Y., AGOSIN, M., OJEDA, J. M., TELLEZ, R., GAULE, C. and MORELLO, A. (1997): Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol Biochem Parasitol 86, 101-6.
64. MICHELIN, M. A., SILVA, J. S. and CUNHA, F. Q. (2005): Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental Trypanosoma cruzi infection. Exp Parasitol 111, 71-9.
65. MIZIARA, A. N., MOLINA, R. J., FERREIRA, B. D., BARBOSA, C. J., DIAS DA SILVA, V. J., PRATA, A. and CORREIA, D. (2006): Cardiac autonomic modulation in hypertensive patients with Chagas disease. Acta Trop 97, 188-95.
66. MOLINA, R. B., MATSUBARA, B. B., HUEB, J. C., ZANATI, S. G., MEIRA, D. A., CASSOLATO, J. L., PAIVA, S. A. and ZORNOFF, L. A. (2006): Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol 113, 188-93.
67. MURTA, S. M., KRIEGER, M. A., MONTENEGRO, L. R., CAMPOS, F. F., PROBST, C. M., AVILA, A. R., MUTO, N. H., DE OLIVEIRA, R. C., NUNES, L. R., NIRDE, P., BRUNAROMERO, O., GOLDENBERG, S. and ROMANHA, A. J. (2006): Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol 146, 151-62.
68. PANIZMON-DOLFI, A. E., PEREZALVAREZ, A. M., LANZA, G., MARQUEZ, E. and CONCEPCION, J. L. (2009): Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas disease. Chemotherapy 55, 228-33.
69. PATRONO, C., GARCÍA RODRÍGUEZ, L. A., LANDOLFI, R. and BAIGENT, C. (2005): Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353, 2373-83.
70. PEREZ-MOLINA, J. A., PEREZAYALA, A., MORENO, S., FERNANDEZ-GONZALEZ, M. C., ZAMORA, J. and LOPEZ-VELEZ, R. (2009): Use of benznidazole to treat chronic Chagas disease: a systematic review with a meta-analysis. J Antimicrob Chemother 64, 1139-1147.
71. PETKOVA, S. B., HUANG, H., FACTOR, S. M., PESTELL, R. G., BOUZAHZAH, B., JELICKS, L. A., WEISS, L. M., DOUGLAS, S. A., WITTNER, M. and TANOWITZ, H. B. (2001): The role of endothelin in the pathogenesis of Chagas disease. Int J Parasitol 31, 499-511.
72. PINGEFILHO, P., TADOKORO, C. E. and ABRAHAMSOHN, I. A. (1999): Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection. Cell Immunol 193, 90-8.
73. PUNUKOLLU, G., GOWDA, R. M., KHAN, I. A., NAVARRO, V. S. and VASAVADA, B. C. (2007): Clinical aspects of the Chagas heart disease. Int J Cardiol 115, 279-83.
74. RAMOS, S. G. AND ROSSI, M. A. (1999): Microcirculation and Chagas disease: hypothesis and recent results. Rev Inst Med Trop Sao Paulo 41, 123-9.
75. RASSI, A., JR., DIAS, J. C., MARIN-NETO, J. A. and RASSI, A. (2009a): Challenges and opportunities for primary, secondary and tertiary prevention of Chagas disease. Heart 95, 524-34.
76. RASSI, A., JR. and RASSI, A. (2009): Predicting prognosis in patients with Chagas disease: Why are the results of various studies so different? Int J Cardiol.
77. RASSI, A., JR., RASSI, A. and MARIN-NETO, J. A. (2009b): Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 104 Suppl 1, 152-8.
78. RASSI, A., JR., RASSI, A. and MARIN-NETO, J. A (2009c): Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 104, 152-8.
79. RASSI, A., JR., RASSI, A. and RASSI, S. G. (2007): Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115, 1101-8.
80. REITHINGER, R., TARLETON, R. L., URBINA, J. A., KITRON, U. and GURTLER, R. E. (2009): Eliminating Chagas disease: challenges and a roadmap. BMJ 338, b1283.
81. REYES, P. A. and VALLEJO, M. (2005): Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev, CD004102.
82. RIBEIRO, A. L., DE CARVALHO, A. C., LOMBARDI, F., TEIXEIRA, M. M. and ROCHA, M. O. (2009a): Enhanced parasympathetic activity in Chagas disease still stands in need of proof. Int J Cardiol 135, 406-8.
83. RIBEIRO, A. L., GIMENEZ, L. E., HERNANDEZ, C. C., DE CARVALHO, A. C., TEIXEIRA, M. M., GUEDES, V. C., BARROS, M. V., LOMBARDI, F. and ROCHA, M. O. (2007): Early occurrence of antimuscarinic autoantibodies and abnormal vagal modulation in Chagas disease. Int J Cardiol 117, 59-63.
84. RIBEIRO, A. L., MORAES, R. S., RIBEIRO, J. P., FERLIN, E. L., TORRES, R. M., OLIVEIRA, E. and ROCHA, M. O. (2001): Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J 141, 260-5.
85. RIBEIRO, C. H., LOPEZ, N. C., RAMIREZ, G. A., VALCK, C. E., MOLINA, M. C., AGUILAR, L., RODRIGUEZ, M., MALDONADO, I., MARTINEZ, R., GONZALEZ, C., TRONCOSO, R., LAVANDERO, S., GINGRAS, A. R., SCHWAEBLE, W. and FERREIRA, A. (2009b): Trypanosoma cruzi calreticulin: a possible role in Chagas disease autoimmunity. Mol Immunol 46, 1092-9.
86. ROCHA, A. L., LOMBARDI, F., DA COSTA ROCHA, M. O., BARROS, M. V., VAL BARROS VDA, C., REIS, A. M. and RIBEIRO, A. L. (2006a): Chronotropic incompetence and abnormal autonomic modulation in ambulatory Chagas disease patients. Ann Noninvasive Electrocardiol 11, 3-11.
87. ROCHA, M. O., NUNES, M. C. and RIBEIRO, A. L. (2009): Morbidity and prognostic factors in chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz 104 Suppl 1, 159-66.
88. ROCHA, N. N., GARCIA, S., GIMENEZ, L. E., HERNANDEZ, C. C., SENRA, J. F., LIMA, R. S., CYRINO, F., BOUSKELA, E., SOARES, M. B., RIBEIRO DOS SANTOS, R. and CAMPOS DE CARVALHO, A. C. (2006b): Characterization of cardiopulmonary function and cardiac muscarinic and adrenergic receptor density adaptation in C57BL/6 mice with chronic Trypanosoma cruzi infection. Parasitology 133, 729-37.
89. ROSSI, M. A. AND RAMOS, S. G. (1996): Coronary microvascular abnormalities in Chagas disease. Am Heart J 132, 207-10.
90. SAMUEL, J., OLIVEIRA, M., CORREA DE ARAUJO, R. R., NAVARRO, M. A. and MUCCILLO, G. (1983): Cardiac thrombosis and thromboembolism in chronic Chagas heart disease. Am J Cardiol 52, 147-51.
91. SATHLERA-VELAR, R., VITELLIA-VELAR, D. M., MASSARA, R. L., DE LANA, M., PINTO DIAS, J. C., TEIXEIRA-CARVALHO, A., ELOI-SANTOS, S. M. and MARTINS-FILHO, O. A. (2008): Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect 10, 103-13.
92. SATHLERA-VELAR, R., VITELLIA-VELAR, D. M., TEIXEIRACAR-VALHO, A. and MARTINS-FILHO, O. A. (2009): Innate immunity and regulatory T-cells in human Chagas disease: what must be understood? Mem Inst Oswaldo Cruz 104, 246-51.
93. SCHMUNIS, G. A. and YADON, Z. E. (2009): Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop.
94. SILVA, J. S., MACHADO, F. S. and MARTINS, G. A. (2003): The role of nitric oxide in the pathogenesis of Chagas disease. Front Biosci 8, s314-25.
95. SIMOES, M. V., PINTYA, A. O., BROMBERG-MARIN, G., SARABANDA, A. V., ANTLOGA, C. M., PAZIN-FILHO, A., MACIEL, B. C. and MARIN-NETO, J. A. (2000): Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas cardiomyopathy. Am J Cardiol 86, 975-81.
96. SOUSA, A. S., XAVIER, S. S., FREITAS, G. R. and HASSLOCHERMORENO, A. (2008): Prevention strategies of cardioembolic ischemic stroke in Chagas disease. Arq Bras Cardiol 91, 306-10.
97. SOUSA, L., ROCHA, M. O., BRITTO, R. R., LOMBARDI, F. and RIBEIRO, A. L. (2009): Chagas disease alters the relationship between heart rate variability and daily physical activity. Int J Cardiol 135, 257-9.
98. TANOWITZ, H. B., BURNS, E. R., SINHA, A. K., KAHN, N. N., MORRIS, S. A., FACTOR, S. M., HATCHER, V. B., BILEZIKIAN, J. P., BAUM, S. G. and WITTNER, M. (1990): Enhanced platelet adherence and aggregation in Chagas disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg 43, 274-81.
99. TANOWITZ, H. B., HUANG, H., JELICKS, L. A., CHANDRA, M., LOREDO, M. L., WEISS, L. M., FACTOR, S. M., SHTUTIN, V., MUKHERJEE, S., KITSIS, R. N., CHRIST, G. J., WITTNER, M., SHIRANI, J., KISANUKI, Y. Y. and YANAGISAWA, M. (2005): Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun 73, 2496-503.
100. TANOWITZ, H. B., MACHADO, F. S., JELICKS, L. A., SHIRANI, J., DE CARVALHO, A. C., SPRAY, D. C., FACTOR, S. M., KIRCHHOFF, L. V. and WEISS, L. M. (2009): Perspectives on Trypanosoma cruziinduced heart disease (Chagas disease). Prog Cardiovasc Dis 51, 524-39.
101. TORRES, F. W., ACQUATELLA, H., CONDADO, J. A., DINSMORE, R. and PALACIOS, I. F. (1995): Coronary vascular reactivity is abnormal in patients with Chagas heart disease. Am Heart J 129, 995-1001.
102. UNE, C., ANDERSSON, J. and ORN, A. (2003): Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferongamma production during experimental infection with Trypanosoma cruzi. Clin Exp Immunol 134, 195-201.
103. URBINA, J. A. (2009a): Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104 Suppl 1, 311-8.
104. URBINA, J. A. (2009b): Specific Chemotherapy of Chagas Disease: Relevance, Current Limitations and New Approaches. Acta Trop.
105. VIOTTI, R., VIGLIANO, C., LOCOCO, B., ALVAREZ, M. G., PETTI, M., BERTOCCHI, G. and ARMENTI, A. (2009): Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7, 157-63.
106. VIOTTI, R., VIGLIANO, C., LOCOCO, B., BERTOCCHI, G., PETTI, M., ALVAREZ, M. G., POSTAN, M. and ARMENTI, A. (2006): Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144, 724-34.
107. WAGHABI, M. C., DE SOUZA, E. M., DE OLIVEIRA, G. M., KERAMIDAS, M., FEIGE, J. J., ARAUJO-JORGE, T. C. and BAILLY, S. (2009): Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas disease. Antimicrob Agents Chemother 53, 4694-701.
108. WAGHABI, M. C., KERAMIDAS, M., FEIGE, J. J., ARAUJO-JORGE, T. C. and BAILLY, S. (2005): Activation of transforming growth factor beta by Trypanosoma cruzi. Cell Microbiol 7, 511-7.
109. WHO (2007): Reporte del grupo de trabajo científico sobre la enfermedad de Chagas: 17-20 de abril de 2005, actualizado en julio de 2007, Buenos Aires, Argentina. World Health Organization. Geneva.
110. WILKINSON, S. R., TAYLOR, M. C., HORN, D., KELLY, J. M. and CHEESEMAN, I. (2008): A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 105, 5022-7.
111. WILLIAMS-BLANGERO, S., MAGALHAES, T., RAINWATER, E., BLANGERO, J., CORREA-OLIVEIRA, R. and VANDEBERG, J. L. (2007): Electrocardiographic characteristics in a population with high rates of seropositivity for Trypanosoma cruzi infection. Am J Trop Med Hyg 77, 495-9.